The efficacy of specific neuromodulators on human refractory chronic cough: a systematic review and meta-analysis

Wei, Weili; Liu, Ruilin; ZhangTong, Yangzi; Qiu, Zhongmin

doi:10.21037/jtd.2016.10.51

Cited by 26 publications

(14 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Severe cough can be an important clinical problem in patients with IPF. A combined approach with pharmacological (including gabapentin [67] or thalidomide [65] in the severest cases) and nonpharmacological (e.g. mucus mobilisation/physical rehabilitation or PSALTI [70]) interventions is preferred in patients with severe cough, due to the limited effect of common anti-tussive drugs.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions

Ferrara

Luppi²,

Birring

et al. 2018

Eur Respir Rev

View full text Add to dashboard Cite

Best supportive care (BSC) is generally defined as all the interventions and the multiprofessional approach aimed to improve and optimise quality of life (QoL) in patients affected by progressive diseases. In this sense, it excludes and might be complementary to other interventions directly targeting the disease. BSC improves survival in patients with different types of cancer. Patients with idiopathic pulmonary fibrosis (IPF) experience a vast range of symptoms during the natural history of the disease and might have a beneficial effect of BSC interventions. This review highlights the current evidence on interventions targeting QoL and gaps for the clinical assessment of BSC in the treatment of IPF patients. Very few interventions to improve QoL or improve symptom control are currently supported by well-designed studies. Sound methodology is paramount in evaluating BSC in IPF, as well as the use of validated tools to measure QoL and symptom control in this specific group of patients.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Although there are no specific trials performed in IPF, a meta-analysis focusing also on gabapentin has shown promising results in relieving sensory neuropathic cough and therefore in the treatment of cough for select cases of refractory chronic cough [67].…”

Section: Coughmentioning

confidence: 99%

Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions

Ferrara

Luppi²,

Birring

et al. 2018

Eur Respir Rev

View full text Add to dashboard Cite

show abstract

“…16 Currently, there is evidence that amitriptyline, gabapentin, pregabalin, tramadol, and bac lofen may benefi t chronic cough patients. 18,19 In a randomized trial in 62 patients receiving gabapentin or placebo, Ryan et al 20 found that the gabapentin group demonstrated signifi cantly improved cough-specifi c quality of life compared with the placebo group (number needed to treat 3.58; P = .004). On the other hand, 10 (31%) of the 32 patients receiving gabapentin experienced adverse effects vs 3 (10%) of the 30 in the placebo group.…”

Section: Neuromodulators For Chronic Coughmentioning

confidence: 99%

A cough that won’t go away: Evaluation and treatment in 2 patients

Lee

Taliercio

Adessa

et al. 2020

CCJM

View full text Add to dashboard Cite

“…Chronic refractory cough (CRC) is a clinically signi cant disorder where the etiologies of chronic cough remain unknown despite comprehensive laboratory investigations or cough is resistant to subsequent speci c therapies even though the causes are identi ed 1,2 . It is also called as cough hypersensitivity syndrome [1][2][3] . The management of CRC remains a challenge.…”

Section: Introductionmentioning

confidence: 99%

Prediction of Therapeutic Efficacy of Gabapentin by Hull Airway Reflux Questionnaire in Chronic Refractory Cough

Zhang

Chen

Dong

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

BackgroundGabapentin is recommended for the treatment of chronic refractory cough. This study aims to identify its therapeutic predictors in a prospective clinical study.Methods179 patients with chronic refractory cough were treated with gabapentin. Prior to the therapy, all patients were assessed by Hull Airway Reflux Questionnaire (HARQ) and inhaled capsaicin test. When the treatment ended and cough resolution was confirmed, a stepwise logistic regression analysis was performed to identify the therapeutic predictors for gabapentin and to establish the prediction equation. ResultsGabapentin treatment achieved a therapeutic success rate of 66.5%. HARQ scores were significantly higher in responders than non-responders to gabapentin (29.79 ± 9.58 vs 21.95 ± 7.83, t = -3.685, P = 0.000), which were positively related to the therapeutic efficacy of gabapentin (r = 0.433, P < 0.01). The optimal cutoff point of 21.5 in HARQ presented with a moderate ability to predict gabapentin efficacy, with a sensitivity of 84.6% and specificity of 63.6%. Multiple logistic regression identified items of “A tickle in your throat, or a lump in your throat” (OR= 7.927, P=0.005), “Cough when you get out of bed in the morning” (OR=7.016, P=0.045) and “Cough with eating” (OR=6.689, P=0.011) as independent predictors. The established logistic regression equation predicted ³ 80% of the treatment success rate of gabapentin, which was verified by consequent preliminary revalidating study in 59 patients.ConclusionsHARQ may be useful to screen patients with chronic refractory cough most likely responsive to gabapentin, and help improve the therapeutic success. Trial registrationhttp://www.chictr.org/; No.: ChiCTR-ONC-13003123

show abstract

The efficacy of specific neuromodulators on human refractory chronic cough: a systematic review and meta-analysis

Cited by 26 publications

References 25 publications

Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions

Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions

A cough that won’t go away: Evaluation and treatment in 2 patients

Prediction of Therapeutic Efficacy of Gabapentin by Hull Airway Reflux Questionnaire in Chronic Refractory Cough

Contact Info

Product

Resources

About